Drug intelligence / Profile preview

TTBT01

Development stage: Unknown
Lead developer: BioTissue
Modality: Tissue Cells → Other Cell Types → Cell Therapies
Administration: Ophthalmic, Topical

Overview

**TTBT01** is a TissueTech investigational Section 351 biologic for ocular-surface regenerative healing. It is a topical ophthalmic preparation containing a morselized, biochemically purified human birth-tissue matrix derived from cryopreserved amniotic membrane and cryopreserved umbilical cord. The product is intended to promote healing of persistent corneal epithelial defects and has been described as having anti-inflammatory, anti-scarring, and anti-angiogenic activity relevant to ocular surface disease and dry eye disease. TissueTech received FDA clearance in March 2021 to proceed with a Phase 2 study.

Beyond the preview

Go deeper on TTBT01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTBT01.

Explore the full profile